T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, will share multiple updates regarding the clinical utility of its expanding portfolio of groundbreaking rapid diagnostics and technology during ASM Microbe 2019 in San Francisco, CA from June 19 to 24.
LEXINGTON, Mass., June 20, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, will share multiple updates regarding the clinical utility of its expanding portfolio of groundbreaking rapid diagnostics and technology during ASM Microbe 2019 in San Francisco, CA from June 19 to 24.
“The T2Bacteria® and T2Candida® panels are the first-and-only FDA cleared tests that can provide direct-from-blood, rapid diagnostics for patients suspected of blood stream infection or sepsis. This patent-protected technological innovation is a major accomplishment, particularly when considering the decades of attempted development efforts from over a half dozen other companies that did not yield FDA cleared tests. Since introducing our T2Bacteria Panel at last year’s meeting, we are proud to share that we’ve altered the course of clinical treatment in meaningful ways, making a significant impact on healthcare facilities and the patients they treat,” said John McDonough, president and chief executive officer of T2 Biosystems. “We look forward to our time at ASM Microbe 2019 as an opportunity to connect with the world’s leading microbiologists and communicate this impact, along with our plans for continuing on this disruptive path as we work to address unmet needs related to sepsis prevention in today’s healthcare environment.”
Throughout the show, T2 Biosystems will offer attendees multiple opportunities to experience new data that underscore the benefits experienced by facilities who have adopted T2 technology. Tom Lowery, PhD, chief scientific officer, T2 Biosystems, will present an Industry Education Workshop, Rapid, Direct-from-Blood Diagnostics that Enable Changes in Clinical Decisions, on Friday, June 21 from 12:00 – 12:45 pm in Theater North in the Exhibit Hall of The George R. Moscone Convention Center.
The presentation will highlight clinical updates regarding current and future applications of T2 technology, including:
- T2Bacteria provides actionable clinical information: New T2Bacteria Panel clinical data being generated by independent commercial users shows its ability to benefit tested patients in the emergency department by providing information that leads to more rapid time to delivery of effective therapy, de-escalation of unnecessary therapy, and helping avoid premature discharge and readmission to the emergency department.
- Meta-analysis of 70 studies highlights significant challenges of empiric therapy (without T2Bacteria and T2Candida): 46.5% of patients are on inappropriate antibiotic therapy with empiric therapy alone, while >90% are on effective therapy after accurate species identification, such as provided by T2Bacteria and T2Candida.
- T2Bacteria clinical patient selection algorithms demonstrate significant clinical impact: Dr. Lowery will review T2Bacteria patient selection algorithms implemented by T2Bacteria customers and summarize emerging clinical utility data of 120 clinical cases demonstrating significant clinical impact. He will also detail multiple cases demonstrating the impact and potential impact of T2Bacteria on clinical outcomes.
- T2Resistance™ Panel provides ≥ two day time advantage compared to conventional methods: The T2Resistance Panel, which was recently granted Breakthrough Device designation by the FDA, is designed to detect 13 resistance genes from both gram-positive and gram-negative pathogens direct from blood. Initial data demonstrates T2Resistance identifies these resistance genes with an average time of 5.3 hours compared to an average of 30 hours (and up to 95 hours) with conventional methods. The T2Resistance Panel is expected to be available for research use only (RUO) in the U.S. and receive CE-Mark for commercial availability in Europe by the end of 2019.
- T2MR® Technology has the potential to provide coverage for ≥99% of bloodstream infections: Dr. Lowery will present feasibility data demonstrating that the T2MR Technology has the capability to potentially detect >250 pathogen species, which would cover ≥99% of blood-borne pathogens responsible for bloodstream infections and sepsis. It has also demonstrated the ability to potentially detect resistance markers for all blood-borne antibiotic resistance threats identified by the Centers for Disease Control (CDC). These diagnostic capabilities could allow the Company to develop a panel that provides comprehensive coverage of bloodstream infections.
The Company will also participate in an Industry & Science Tech Talk on Saturday, June 22 at 11:00 am in the Innovation Zone (Booth #4811) and host multiple in-booth presentations, including Rapid Culture Independent Detection of Resistance Genes Direct from Whole Blood by T2MR® throughout the show in Booth #1443, where its products will be on display for the duration of the meeting.
T2 Biosystems is the company behind the T2Bacteria Panel, the first and only FDA-cleared test to identify sepsis-causing bacterial pathogens directly from whole blood in 3 to 5 hours without the need to wait for blood culture, allowing patients to be placed on targeted antibiotic therapy faster. The T2Bacteria Panel is one of several panels that are approved or in development that are run on the Company’s T2Dx® Instrument, which is powered by miniaturized magnetic resonance (T2MR®) technology.
